Merck & Co. Calls Active Ahead of Drug Trial Results

MRK – Merck & Co., Inc. – A flurry of near-term bullish activity on the drug maker caught our eye this afternoon. It looks like some investors are acquiring in- and out-of-the-money call options in the November contract ahead of the impending release of results from an advanced trial of Merck’s drug to fight heart disease by increasing good cholesterol levels. Options traders are prepared to make money if positive results wind up sending Merck’s shares higher next week. Shares in Merck & Co., Inc. are currently flat on the day at $35.05 as of 12:30 pm. Investors itching for a rally picked up more than 5,400 now in-the-money calls at the November $35 strike for an average premium of $0.51 each. Call buyers at this strike profit if MRK’s shares rally 1.3% to surpass the average breakeven price of $35.51 by expiration day in November. Bullish sentiment spread to the higher November $36 strike where some 4,900 calls were coveted at an average premium of $0.18 a-pop. Traders holding these contracts make money if shares surge 3.2% to trade above the average breakeven price of $36.18 ahead of expiration. Finally, call activity at the November $37 strike was motivated by sellers. It appears that the majority of the more than 7,000 calls exchanged at that strike were sold 5,000 times for $0.05 apiece. Open interest is more than sufficient to cover volume today, and the sale of the calls may be a closing position. More than 38,670 option contracts have changed hands on the drug maker as of 12:50 pm.

About Andrew Wilkinson 1023 Articles

Affiliation: Interactive Brokers

Andrew Wilkinson is the senior market analyst at Interactive Brokers Group, where he provides daily commentary and analysis on U.S. equity options trading throughout the trading day. Andrew provides webinars designed to explain option-related trading scenarios covering futures, fixed income, forex and equities.

Interactive Brokers: Interactive Brokers offers direct market access to around 80 electronic global markets from a single account. Successful traders and investors understand that superior technology and lower trading costs can result in greater returns. For 32 years we have been building direct access trading technology that delivers real advantages to professionals worldwide. With consolidated equity capital of US $4.4 billion, IB and its affiliates exceed 1,000,000 trades per day. In addition, our prudent and conservative risk policies make Interactive Brokers a safe haven for your money. Discover some of the reasons why IB, the largest independent US broker/dealer, is the professional traders' and investors' choice.

Visit: Interactive Brokers

Be the first to comment

Leave a Reply

Your email address will not be published.